Essential elements of personalized medicine

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 2, 2014, Pages 193-197

  Burke, Wylie ^a   Brown Trinidad, Susan ^a   Press, Nancy A ^b,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Genetics; Genomics; Health technology assessment; Personalized medicine; Pharmacogenomics; Prostate cancer

Indexed keywords

ARTICLE; CANCER GENETICS; CANCER RISK; CANCER SCREENING; FAMILY HISTORY; GENETIC RISK; GENETIC SCREENING; GENOMICS; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH PROMOTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; PERSONAL VALUE; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; SOCIAL DETERMINANTS OF HEALTH;

GENETICS; GENOMICS; HEALTH TECHNOLOGY ASSESSMENT; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PROSTATE CANCER;

DECISION MAKING; DELIVERY OF HEALTH CARE; GENETIC TESTING; GENOMICS; HEALTH SERVICES ACCESSIBILITY; HUMANS; INDIVIDUALIZED MEDICINE; MALE; PHYSICIAN-PATIENT RELATIONS; PROSTATIC NEOPLASMS;

EID: 84892547340     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.09.002     Document Type: Article

References (21)

1. Yurkiewicz S. The prospects for personalized medicine. Hastings Cent Rep 2010, 40:14-16.
2. Tutton R. Personalizing medicine: futures present and past. Soc Sci Med 2012, 75:1721-1728.
3. Juengst E.T., Settersten R.A., Fishman J.R., McGowan M.L. After the revolution? Ethical and social challenges in "personalized genomic medicine". Per Med 2012, 9:429-439.
4. Phillips E., Mallal S. Successful translation of pharmacogenetics into the clinic: the abacavir example. Mol Diagn Ther 2009, 13:1-9.
5. Mallal S., Phillips E., Carosi G., et al. PREDICT-1 study team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008, 358:568-579.
6. Eisenberg J.M. Ten lessons for evidence-based technology assessment. J Am Med Assoc 1999, 282:1865-1869.
7. US Preventive Services Task Force. Recommendations on prostate cancer screening. 〈〉. http://www.uspreventiveservicestaskforce.org/prostatecancerscreening.htm.
8. UsTOO. 〈〉. http://www.ustoo.org/Early_Detection.asp.
9. Gaster B., Edwards K., Trinidad S.B., Gallagher T.H., Braddock C.H. Patient-centered discussions about prostate cancer screening: a real-world approach. Ann Intern Med 2010, 153:661-665.
10. Starks H., Trinidad S.B. Choose your method: a comparison of phenomenology, discourse analysis, and grounded theory. Qual Health Res 2007, 17:1372-1380.
11. Pomerantz M.M., Freedman M.L. The genetics of cancer risk. Cancer J 2011, 17:416-422.
12. Burton H., Chowdhury S., Dent T., Hall A., Pashayan N., Pharoah P. Public health implications from COGS and potential for risk stratification and screening. Nat Genet 2013, 45:349-351.
13. Schoenborn JR, Nelson PS, Fang M. Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification. Clin Cancer Res. 2013. [Epub ahead of print].
14. Genome-Based Therapeutics: Targeted Drug Discovery and Development-Workshop Summary. National Academy of Sciences 2012, IOM (Institute of Medicine), The National Academies Press, Washington, DC.
15. Burke W., Holland S., Kuszler P., Starks H., Press N. Translational genomics: seeking a shared vision of benefit. Am J Bioeth 2008, 8:54-56.
16. Emanuel E.J., Fuchs V.R., Garber A.M. Essential elements of a technology and outcomes assessment initiative. J Am Med Assoc 2007, 298:1323-1325.
17. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) recommendations. 〈〉. http://www.egappreviews.org/recommendations/index.htm.
18. Wilkes M., Srinivasan M., Cole G., Tardif R., Richardson L.C., Plescia M. Discussing uncertainty and risk in primary care: recommendations of a multi-disciplinary panel regarding communication around prostate cancer screening. J Gen Intern Med 2013, [Epub ahead of print].
19. Freeman V.L., Ricardo A.C., Campbell R.T., Barrett R.E., Warnecke R.B. Association of census tract-level socioeconomic status with disparities in prostate cancer-specific survival. Cancer Epidemiol Biomarkers Prev 2011, 2150-2159.
20. James RJ, BlackBird A, Gold DE, Trinidad SB. Factors that influence mammography use among older American Indian and Alaska Native women. J Transcult Nurs, In press.
21. Murray C.J., Kulkarni S.C., Michaud C., Tomijima N., Bulzacchelli M.T., Iandiorio T.J., et al. Eight Americas: investigating mortality disparities across races, counties, and race-counties in the United States. PLoS Med 2006, 3:e260. [Erratum in: PLoS Med. 2006;3(12):e545].